Patients not responding to fludarabine-based treatments display higher UGT2B17 expression, which is also induced in B-CLL cells by antileukemics treatments, namely by ibrutinib [2, 3]. This evidence concerns the gene UGT2B17 and B-cell chronic lymphocytic leukemia.